Abstract: A sensor cleaning apparatus, for cleaning a sensor field of a sensor, in particular a LiDAR sensor, of a vehicle, includes at least one wiper drive housing, which houses at least a majority of at least one wiper drive unit. At least one wiper is arranged at least partially outside of the wiper drive housing and is configured to clean the sensor field by way of a wiping motion. At least one wiper receiving element is provided for transferring a drive movement from the wiper drive unit to the wiper. The sensor cleaning apparatus further includes a sealing unit configured for an at least water-tight seal of the wiper drive housing and includes at least one movable passage opening for the wiper receiving element and/or for the wiper.

Abstract: In a process for preparing mevinolin by fermentation of a biomass in a fermentation liquor, which includes dissolving mevinolin from the biomass into the fermentation liquor, and separating the biomass from the fermentation liquor to obtain a separated fermentation liquor, separating the mevinolin from the separated fermentation liquor, and recovering the end product, the improvement which comprises carrying out the dissolving at a pH between about 7.5 and about 10, and the separating of the mevinolin is carried out at a pH between about 4.5 and about 1.

Abstract: In a process for preparing mevinolin by fermentation of a biomass in a fermentation liquor, which includes dissolving mevinolin from the biomass into the fermentation liquor, and separating the biomass from the fermentation liquor to obtain a separated fermentation liquor, separating the mevinolin from the separated fermentation liquor, and recovering the end product, the improvement which comprises carrying out the dissolving at a pH between 7.5 and about 10, and the separating of the mevinolin is carried out at a pH between about 4.5 and about 1.

Abstract: The invention relates to a compound of formula (I) ##STR1## wherein X is a pharmacologically acceptable anion,R.sub.1 and R.sub.2 are independently of each other hydrogen, or an --OY group in which Y is hydrogen, an .alpha.-aminoacyl, or a C.sub.1-5 aminoalkyl residue,R.sub.3, R.sub.4 and R.sub.7 are independently of each other hydrogen, or a C.sub.1-5 alkyl residueR.sub.5 is hydrogen, and .alpha.-aminoacyl, or a C.sub.1-5 alkyl residue, andR.sub.6 is hydrogen, OH.sup.-, or a C.sub.1-5 alkyl residue,and pharmaceutically acceptable salts and esters thereof; and to condensation processes for preparing them.

Abstract: The subject matter of the invention is a process for the preparation of carboxylic acids and derivatives of them of the general formula ##STR1## wherein R means hydrogen, or a C.sub.1-4 alkyl or a (C.sub.1-5 alkoxy)carbonyl group,R.sub.1 is as defined in claim 1,R.sub.7 stands for hydrogen or a C.sub.1-7 alkyl group andR.sub.8 means hydrogen or a carboxyl group.

Abstract: A process is disclosed for the solution chromatographic purification of cyclosporin A from a starting mixture containing one or more of cyclosporin A, B, C, other cyclosporin components that are more polar or more apolar than cyclosporin A, and other like contaminants, by heating the starting mixture or an evaporation residue thereof to a temperature from about 80.degree. C. to about 115.degree. C., melting the heated starting mixture, and carrying out solution chromatography of the melted material, suitably first in a 48:50:2 mixture of chloroform, dichloromethane, and ethanol, and then in a mixture of like proportions, of the solvents chloroform, ethylacetate, and ethanol.

Abstract: A process for the preparation of high-purity deferoxamine salts from filtered fermentation liquors containing deferoxamine B as active ingredient by the adsorption of the active ingredient onto an ion exchange resin and the subsequent dissolution and purification thereof, which comprises carrying out the separation of the deferoxamine salt subsequent to the concentration of the eluate by salting out from an aqueous solution or from a mixture of water and an organic solvent and purifying it by repeated salting out and/or by methods known per se, and optionallya) preparing the methanesulfonate salt by known methods, orb) passing the aqueous solution of the deferoxamine salt trough an ion exchange resin containing methanesulfonate anions as counter ions and recovering the methanesulfonate salt from the effluent, preferably by lyophilization.

Abstract: The subject matter of the invention is a process for the preparation of carboxylic acids and derivatives of them of the general formula ##STR1## wherein R means hydrogen, or a C.sub.1-4 alkyl or a (C.sub.1-5 alkoxy)carbonyl group,R.sub.1 is as defined in claim 1,R.sub.7 stands for hydrogen or a C.sub.1-7 alkyl group andR.sub.8 means hydrogen or a carboxyl group,by reacting a 1,3-dioxane-4,6-dione derivative of the general formula ##STR2## wherein R.sub.9 stands for a C.sub.1-4 alkyl group or a phenyl group, optionally monosubstituted by halogen andR.sub.10 stands for hydrogen or a C.sub.1-5 alkyl group orR.sub.9 and R.sub.10 together form a pentamethylene group,and an aldehyde or ketone of the general formula ##STR3## in the presence of formic acid.

Abstract: The invention relates to novel thiazolidine-4(S)-carboxylic acid derivatives of the general formula (I) ##STR1## wherein R.sup.1 stands for an optionally substituted furyl, pyrrolyl, thienyl, benzofuryl, benzopyrrolyl, benzothienyl, phenyl, pyridyl, quinolinyl, isoquinolinyl or indanyl group or a C.sub.1-4 alkyl or C.sub.2-4 alkenyl group optionally substituted by a hydroxyl, carboxyl or halogen fenoxy group,stands for hydrogen, an alkaline metal or an alkaline earth metal atom or an optionally substituted C.sub.1-4 alkyl group or aryl group;R.sup.3 represents hydrogen or an optionally substituted C.sub.1-4 alkyl or acyl group or aryl groupas well as their salts.Further on, the invention relates to pharmaceutical preparations containing these compounds and to a process for preparing these compounds and preparations.The compounds of the invention are useful for treating or preventing liver damages of either natural or experimental origin.

Abstract: This invention relates to the new 1,3-bis-(dimethylamino)-2-propyl-4-chlorophenoxyacetate of the Formula (I) ##STR1## acid addition salts thereof, a process for the preparation of the same and pharmaceutical compositions comprising the said compounds.The novel compound of the present invention corresponds to the Formula (I). This compound stimulates the function of the brain cells and thereby mental activity.The compound of the Formula (I) can be prepared by esterifying (4-chlorophenoxy)-acetic acid or a functional reactive derivative thereof with 1,3-bis-(dimethylamino)-2-propanol or a halogeno derivative thereof in a manner known per se.

Abstract: The invention relates to a process for the preparation of an oxytetracycline-calcium silicate complex salt from fermentation broth.By the process according to the invention the valuable antibiotic oxytetracycline may be separated from the fermentation broth in an easy manner. The complex obtained according to (a) contains up to 50% of antibiotic and is suitable for the processing in the pharmaceutical industry while the product according to (b) contains 10 to 20% of antibiotic and may be used as fodder additive directly.

Abstract: The invention relates to a new process for the preparation of easy-flowing (flowable) oxytetracyclin hydrochloride. According to the process of the invention, the crude, dry or filter-wet oxytetracyclin hydrochloride consisting of needle-shaped crystals is boiled with an organic solvent forming an azeotropic mixture with water, optionally a part of the solvent is distilled off in a form of an azeotropic mixture, then the mixture is cooled and the precipitated oxytetracyclin hydrochloride consisting of spherical crystals is separated and dried.Oxytetracyclin hydrochloride exists in two various crystal forms, the one of which is needle-shaped, while the other one consists of orthorhombic sheets. The crystals of this latter form are capable of forming spherical particles by coalescence. The crystal form consisting of spherical particles is much more useful for the pharmaceutical industry.